CFA
CORT icon

Carroll Financial Associates’s Corcept Therapeutics CORT Stock Holding History

Carroll Financial Associates’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-56
Closed -$1K – 1662
2021
Q3 		$1K Buy
+56
New +$1.17K ﹤0.01% 1623

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carroll Financial Associates's CORT Position: Q4 2021 in Review

Carroll Financial Associates sold out of Corcept Therapeutics (CORT) in Q4 2021, closing a stake of 56 shares — an estimated $1K sold.

Carroll Financial Associates first reported a position in CORT in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 208 funds tracked by Wall St. Rank hold CORT as of Q4 2021.

  • Carroll Financial Associates reported no remaining Corcept Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Carroll Financial Associates sold 56 Corcept Therapeutics shares in Q4 2021, an estimated $1K.
  • Carroll Financial Associates first reported a position in Corcept Therapeutics in Q3 2021 and held it in 1 quarter.
  • Carroll Financial Associates's Corcept Therapeutics position peaked at $1K in Q3 2021.
  • 208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.